Form 4: Ultragenyx Director Shehnaaz Suliman Reports Stock and Option Awards
SEC Form 4 Filing
Director Shehnaaz Suliman reports acquisition of restricted stock units and stock options in Ultragenyx Pharmaceutical Inc.
Summary
- Shehnaaz Suliman, a director at Ultragenyx Pharmaceutical Inc., filed a Form 4 detailing changes in beneficial ownership.
- On May 15, 2025, Suliman acquired 5,740 shares of common stock through restricted stock units (RSUs) and 10,787 stock options.
- The RSUs vest on the earlier of the company's next Annual Meeting of Stockholders or May 15, 2026.
- The stock options, with an exercise price of $34.84, also vest on the earlier of the company's next Annual Meeting of Stockholders or May 15, 2026.
- Following these transactions, Suliman directly owns 25,940 shares of common stock and 10,787 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock and option awards to a director. While insider ownership is generally viewed positively, this is a routine grant.
Positives
- The director's acquisition of shares and options could be seen as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule of the RSUs and stock options is tied to the company's next Annual Meeting of Stockholders or May 15, 2026, indicating a potential future event to watch.
Industry Context
Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's stock. This filing is specific to Ultragenyx Pharmaceutical Inc., a company in the biotechnology sector.
Stakeholder Impact
- The director's stock ownership aligns her interests with those of other shareholders.
- The vesting of RSUs and stock options may incentivize the director to contribute to the company's long-term success.
Next Steps
- Monitor future Form 4 filings by Ultragenyx insiders for further insights into their investment activities.
- Track the company's stock performance and news related to Ultragenyx Pharmaceutical Inc.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of the transaction: acquisition of RSUs and stock options. |
| 05/15/2026 | Date of full vesting of RSUs and stock options if the Annual Meeting of Stockholders does not occur before this date. |
| 05/19/2025 | Date of the Form 4 filing. |
Keywords
Form 4, Ultragenyx, Director, Stock Options, RSUs, Beneficial Ownership, Shehnaaz Suliman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.